(VIANEWS) – Shares of Viking Therapeutics (NASDAQ: VKTX) dropped by a staggering 27.32% in 30 days from $3.67 to $2.67 at 12:52 EST on Friday, after five sequential sessions in a row of losses. NASDAQ is dropping 2.22% to $10,821.30, after three consecutive sessions in a row of losses.

Viking Therapeutics’s last close was $2.85, 59.55% under its 52-week high of $7.05.

About Viking Therapeutics

Viking Therapeutics, Inc. is a biopharmaceutical company at the clinical stage. It focuses its efforts on developing novel treatments for metabolic and endocrinological disorders. VK2809 is the company’s leading drug candidate. It is an oral tissue-subtype select agonist and receptor-subtype selective antagonist of the thyroid hormone receptor alpha (TRss). The Phase IIb clinical trial is underway to treat non-alcoholic steatohepatitis patients. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRss for X-linked adrenoleukodystrophy. It was founded in 2012 in San Diego, California.


Today’s last reported volume for Viking Therapeutics is 287036 which is 67.36% below its average volume of 879450.

The company’s growth estimates for the current quarter and the next is a negative 35.3% and a negative 50%, respectively.


Viking Therapeutics’s last week, last month’s, and last quarter’s current intraday variation average was a positive 1.04%, a negative 0.72%, and a positive 3.55%, respectively.

Viking Therapeutics’s highest amplitude of average volatility was 1.75% (last week), 1.99% (last month), and 3.55% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Viking Therapeutics’s stock is considered to be overbought (>=80).

Viking Therapeutics’s Stock Yearly Top and Bottom Value

Viking Therapeutics’s stock is valued at $2.67 at 12:52 EST, way below its 52-week high of $7.05 and way above its 52-week low of $2.02.

Viking Therapeutics’s Moving Average

Viking Therapeutics’s value is way under its 50-day moving average of $3.39 and way under its 200-day moving average of $3.33.

More news about Viking Therapeutics (VKTX).


Please enter your comment!
Please enter your name here